Navigation Links
Discovery Labs Reports Fourth Quarter 2012 Financial Results
Date:3/13/2013

; "As we anticipate the availability of SURFAXIN® drug product in the second quarter, our specialty field force has been focused primarily on securing hospital formulary acceptance for SURFAXIN, as well as adoption of AFECTAIR®.  We continue to make progress on our AEROSURF® development program and plan to initiate our phase 2 clinical program in the fourth quarter of 2013."

Selected Program Updates:

SURFAXIN: SURFAXIN (lucinactant) intratracheal suspension is the first synthetic, peptide-containing surfactant approved by the Food and Drug Administration (FDA) and provides healthcare practitioners an alternative to animal-derived surfactants to prevent respiratory distress syndrome (RDS) in premature infants.  In the third quarter of 2012, the Company determined that one of the analytical chemistry methods used to assess SURFAXIN drug product conformance to specifications required improvement and that an update to product specifications was needed. As a result, the Company delayed the commercial launch of SURFAXIN.  The Company proactively communicated these findings to the FDA, improved and validated the analytical chemistry method, and submitted updated product specifications to the FDA.  The planned activities remain on track, and, pending confirmation from the FDA regarding the updated product specifications; the Company believes that SURFAXIN will be available for commercial sale in the second quarter of 2013.  

AEROSURF:  The Company is developing AEROSURF as a drug/device combination product to potentially allow neonatal practitioners to deliver aerosolized KL4 surfactant to premature infants without the need for invasive endotracheal intubation.  If efforts are successful, AEROSURF could enable the treatment of a significantly greater number of premature infants at risk for RDS.  The Company is progressing with third-party medical device ex
'/>"/>

SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. E-Discovery Industry Veteran Joins VeDISCOVERY LLC
2. Innovative Research Collaboration to Advance Next-Generation Methods in Peptide Discovery for Cosmeceuticals
3. Alzheimers Drug Discovery Foundation Awards Grant To CohBar to Develop A Novel Peptide Therapeutic For Alzheimers Disease
4. PrimerLife.com, a Skolkovo Participant Company, Celebrates Anniversary of DNA Discovery with Launch of New Social Network
5. RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
6. Emerald Logic announces collaboration with Kings College London on quantitative biomarker discovery
7. Drug Discovery and Development Market in Asia - Partnerships Between MNCs and Asian Academic Institutions and Healthcare Research Organizations are Driving R&D Innovation
8. Harrington Discovery Institute at University Hospitals Case Medical Center Announces Grant Funding to Physician-Scientists at Major Academic Medical Centers to Support New Drug Development
9. GDS International Announces "Industry Leader of the Year" Award at its Fourth Annual European Pharmaceutical Drug Discovery Summit
10. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
11. Rochester Medical Corporation to Participate in The Benchmark Company, LLC Micro Cap Discovery Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 2015  Semler Scientific, Inc. (Nasdaq: SMLR ), ... healthcare insurers and physician groups, today reported financial results ... "In the second quarter of 2015, Semler ... of 54%, quarter over quarter revenue growth of 8%, ... of FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., ...
(Date:7/30/2015)... , July 30, 2015 Edwards Lifesciences Corporation (NYSE: ... heart valves and hemodynamic monitoring, today announced that Robert ... Directors. "Bob is an ardent champion for innovation ... privilege to have him on Edwards, board as we pursue ... Edwards, chairman and CEO.  "Bob has provided a valuable perspective ...
(Date:7/30/2015)... 30, 2015  Tandem Diabetes Care®, Inc. (NASDAQ: ... manufacturer of the t:slim® and t:flex™ Insulin Pumps, ... Development Agreements with Dexcom, Inc. to allow the ... the Dexcom G5 and G6 continuous glucose monitoring ... pump platform with Dexcom,s future CGM systems is ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3
... N.Y., June 30 XTL,Biopharmaceuticals Ltd. (Nasdaq: XTLB ... randomization into its Phase 2b study of Bicifadine,-- a ... of diabetic neuropathic pain. 350 patients were randomized into,the ... expects to,have the last patient complete the study in ...
... Co (NYSE:,LLY) and Boehringer Ingelheim today announced that ... of the European Medicines Agency,(EMEA) has issued a ... for the treatment of Generalised Anxiety,Disorder (GAD)., ... of five clinical studies,-- four double-blind placebo-controlled studies ...
Cached Medicine Technology:XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Announces Completion of Patient Randomization Into the Bicifadine Phase 2b Clinical Trial for the Treatment of Diabetic Neuropathic Pain 3European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 2European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 3European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 4European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 5European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder 6
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... August 01, 2015 , ... Lume Wellness creators Alex, Robert, and Sam ... on the Apple AppStore. , The app is designed to track various metrics ... a tool to view personal health and use this information for positive behavior modification. ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured ... latest and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, ... viewers allows users to clarify, edit and delete any message including ones already sent. ...
(Date:7/31/2015)... ... 31, 2015 , ... That’s right, the STASH awards have ... The Significant Technological Achievements in Secretive Horticulture (or STASH) Awards, featured in High ... that have stood the test of time. These include lighting products, organic and ...
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Lume Wellness Launches Health and Fitness Tracker iPhone App 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... in adults, revs up calorie-burning, experts say , , WEDNESDAY, April ... -- the brown fat revolution, that is. , ... verified that adult humans do possess this "good," slimming form ... and rodents. , The tissue is metabolically active and the ...
... 8 /PRNewswire-FirstCall/ - IMRIS Inc. (TSX: IM) ("IMRIS" or ... intra-operative MR held at PLA 301 Hospital in Beijing ... USA, Germany, Taiwan and Hong Kong attended the inaugural ... neurosurgery. The conference was opened by Dir Chen Xiaohong, ...
... Michael Eskew Named New Chair of Audit CommitteeINDIANAPOLIS, April 8 ... (NYSE: LLY ) today announced that J. Michael ... 2009. Mr. Cook, the retired chairman and chief executive officer ... the Lilly board since 2005. Mr. Cook has been a ...
... Serve Health Professionals, Instructors and Counselors , ... Today the American Psychological Association (APA) notified Humanitas, ... stringent criteria to offer continuing education credit hours ... programs. Humanitas offers a variety of educational ...
... Researchers and Updates on Key Discoveries, Plus Panel ... 8 Internationally renowned physician-scientists will discuss the ... plus important recent discoveries in translational cancer research, ... Research Foundation Clinical Investigator Symposium.The April ...
... 8 ORLANDO, Fla., April 8 James ... opening of his new dental practice, DellagioDentist.com, ... Orlando. This new dental practice, located at ... 8.(Photo: http://www.newscom.com/cgi-bin/prnh/20090408/CG96485 )Dr. Trantham and ...
Cached Medicine News:Health News:A Fat That May Keep You Thin 2Health News:A Fat That May Keep You Thin 3Health News:Neurosurgeons from around the world gather at PLA 301 Hospital in China 2Health News:J. Michael Cook to Retire from Lilly Board of Directors 2Health News:Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psychologists 2Health News:Humanitas Approved by American Psychological Association (APA) as Provider of Continuing Education Credits to Psychologists 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 2Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 3Health News:Top Physician-Scientists Discuss State of Cancer Research at Damon Runyon Cancer Research Foundation Symposium 4Health News:New Family Dental Practice Opens in Orlando 2
... display of corneal layers: endothelium, ... epithelial layers. Accurate analysis of ... keratocytes, nerve fibres, basal & ... surgery and pathology: optical pachymetry, ...
Ahmed Glaucoma Valve (small size)....
... Long-term biocompatibility is established. Provides a robust ... ensure correct positioning on the globe. Pressure ... which, when covered by Tenons tissue, acts ... postoperative hypotony. The range of implants allows ...
... Goldmann standard automatic or manual ... with white/white, blue/yellow or red/white stimuli/background ... or classic 4-2 threshold strategy. Examination ... grids (including 30-2, 24-2, and 10-2). ...
Medicine Products: